Relief Therapeutics Holding AG (RLFTF)
USD 4.9
(0.0%)
USD 4.9
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.31 Million CHF | 40.7% |
| 2022 | 3.06 Million CHF | 1.66% |
| 2021 | 3.01 Million CHF | 238.27% |
| 2020 | 891 Thousand CHF | -7.38% |
| 2019 | 962 Thousand CHF | -79.27% |
| 2018 | 4.64 Million CHF | 358.5% |
| 2017 | 1.01 Million CHF | 15.26% |
| 2016 | 878 Thousand CHF | -80.93% |
| 2015 | 4.6 Million CHF | 18.05% |
| 2014 | 3.9 Million CHF | -53.86% |
| 2013 | 8.45 Million CHF | 208.3% |
| 2012 | 2.74 Million CHF | 305.02% |
| 2011 | 676.98 Thousand CHF | 72.03% |
| 2010 | 393.52 Thousand CHF | 18.8% |
| 2009 | 331.24 Thousand CHF | -35.8% |
| 2008 | 515.94 Thousand CHF | -86.33% |
| 2007 | 3.77 Million CHF | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 12 Thousand CHF | -99.72% |
| 2024 Q2 | 12 Thousand CHF | 20041.67% |
| 2023 Q2 | 3.23 Million CHF | -19.45% |
| 2023 FY | 4.31 Million CHF | 40.7% |
| 2023 Q4 | 4.31 Million CHF | 13.84% |
| 2023 Q3 | 3.78 Million CHF | 16.92% |
| 2023 Q1 | 4.02 Million CHF | 31.23% |
| 2022 Q4 | 3.06 Million CHF | -21.44% |
| 2022 Q1 | 3.71 Million CHF | 23.39% |
| 2022 Q3 | 3.9 Million CHF | 38.15% |
| 2022 FY | 3.06 Million CHF | 1.66% |
| 2022 Q2 | 2.82 Million CHF | -24.09% |
| 2021 Q4 | 3.01 Million CHF | -23.37% |
| 2021 FY | 3.01 Million CHF | 238.27% |
| 2021 Q1 | 8.85 Million CHF | 894.16% |
| 2021 Q2 | 7.99 Million CHF | -9.72% |
| 2021 Q3 | 3.93 Million CHF | -50.82% |
| 2020 Q4 | 891 Thousand CHF | 0.0% |
| 2020 Q2 | 1.74 Million CHF | -48.81% |
| 2020 Q1 | 3.4 Million CHF | 254.37% |
| 2020 FY | 891 Thousand CHF | -7.38% |
| 2020 Q3 | 891 Thousand CHF | -48.94% |
| 2019 FY | 962 Thousand CHF | -79.27% |
| 2019 Q4 | 962 Thousand CHF | -44.68% |
| 2019 Q1 | 1.37 Million CHF | -70.3% |
| 2019 Q2 | 742 Thousand CHF | -46.15% |
| 2019 Q3 | 1.73 Million CHF | 134.37% |
| 2018 Q2 | 5.39 Million CHF | 422.58% |
| 2018 Q4 | 4.64 Million CHF | 340.65% |
| 2018 FY | 4.64 Million CHF | 358.5% |
| 2018 Q3 | 1.05 Million CHF | -80.47% |
| 2018 Q1 | 1.03 Million CHF | 1.98% |
| 2017 FY | 1.01 Million CHF | 15.26% |
| 2017 Q4 | 1.01 Million CHF | 0.0% |
| 2017 Q3 | 1.01 Million CHF | 15.53% |
| 2017 Q2 | 876 Thousand CHF | 0.0% |
| 2017 Q1 | 876 Thousand CHF | -0.23% |
| 2016 FY | 878 Thousand CHF | -80.93% |
| 2016 Q4 | 878 Thousand CHF | 0.0% |
| 2016 Q3 | 878 Thousand CHF | -74.15% |
| 2016 Q2 | 3.39 Million CHF | 0.0% |
| 2016 Q1 | - CHF | -100.0% |
| 2015 Q2 | 3.03 Million CHF | 0.0% |
| 2015 FY | 4.6 Million CHF | 18.05% |
| 2015 Q4 | 4.6 Million CHF | 0.0% |
| 2014 Q4 | 3.9 Million CHF | 0.0% |
| 2014 FY | 3.9 Million CHF | -53.86% |
| 2014 Q2 | 8.97 Million CHF | 0.0% |
| 2013 FY | 8.45 Million CHF | 208.3% |
| 2013 Q2 | 2.62 Million CHF | 0.0% |
| 2013 Q4 | 8.45 Million CHF | 0.0% |
| 2012 Q4 | 2.74 Million CHF | 0.0% |
| 2012 FY | 2.74 Million CHF | 305.02% |
| 2012 Q2 | 2.11 Million CHF | 0.0% |
| 2011 FY | 676.98 Thousand CHF | 72.03% |
| 2011 Q2 | 399.86 Thousand CHF | 0.0% |
| 2011 Q4 | 676.98 Thousand CHF | 0.0% |
| 2010 Q2 | 238.67 Thousand CHF | 0.0% |
| 2010 FY | 393.52 Thousand CHF | 18.8% |
| 2010 Q4 | 393.52 Thousand CHF | 0.0% |
| 2009 Q4 | 331.24 Thousand CHF | 0.0% |
| 2009 Q2 | 460.31 Thousand CHF | 0.0% |
| 2009 FY | 331.24 Thousand CHF | -35.8% |
| 2008 FY | 515.94 Thousand CHF | -86.33% |
| 2008 Q4 | 515.94 Thousand CHF | 0.0% |
| 2007 FY | 3.77 Million CHF | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 89.537% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -4.586% |
| SQZ Biotechnologies Company | 27.47 Million USD | 84.307% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 90.061% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 85.518% |
| Mesoblast Limited | 118.7 Million USD | 96.368% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -354.617% |
| Genus plc | 233.1 Million USD | 98.151% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -47.114% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -220.858% |
| Marizyme, Inc. | 18.71 Million USD | 76.968% |
| ContraFect Corporation | 2.88 Million USD | -49.636% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -474.8% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -3081.855% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -198.067% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -85.343% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 23.812% |
| MultiCell Technologies, Inc. | 202.58 USD | -2127948.178% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 92.501% |
| EV Biologics, Inc. | 1.49 Million USD | -188.409% |
| Q BioMed Inc. | 4.1 Million USD | -4.891% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 86.976% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -584.202% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -250.955% |
| Biomind Labs Inc. | 735.54 Thousand USD | -486.098% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 97.487% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 66.831% |
| Skye Bioscience, Inc. | 4.61 Million USD | 6.593% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -385.438% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2946.256% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 26.572% |
| IMV Inc. | 28.88 Million USD | 85.075% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -16661.927% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -90.889% |
| GB Sciences, Inc. | 1.75 Million USD | -145.04% |
| Alpha Cognition Inc. | 1.22 Million USD | -253.253% |
| HST Global, Inc. | 98.31 Thousand USD | -4284.707% |
| CSL Limited | 12.18 Billion USD | 99.965% |
| Halberd Corporation | 150 Thousand USD | -2774.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -332.684% |
| Resverlogix Corp. | 6.49 Million USD | 33.585% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -802.827% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1586.673% |
| argenx SE | 20 Million USD | 78.445% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 90.538% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -59.154% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -42061.369% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.968% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -2048.881% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -79.796% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1780.144% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 93.627% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -42.456% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1098.465% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 78.793% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2800.023% |
| BioStem Technologies, Inc. | 4.71 Million USD | 8.499% |
| ONE Bio Corp. | 19.71 Million USD | 78.133% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1623.146% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1633.274% |
| Agentix Corp. | 50 Thousand USD | -8522.0% |
| LadRx Corporation | 33.6 Thousand USD | -12728.066% |
| Cell Source, Inc. | 9.25 Million USD | 53.416% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -470.084% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -470.084% |
| NovAccess Global Inc. | 2.19 Million USD | -95.965% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 39.048% |
| Itoco Inc. | 228.37 Thousand USD | -1787.668% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1943.37% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 13.486% |
| Kadimastem Ltd | 891.22 Thousand USD | -383.716% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -972.791% |
| CytoDyn Inc. | 30.07 Million USD | 85.666% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -790.18% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1125.248% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 44.872% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3419.184% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1290.645% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 8.96% |
| International Stem Cell Corporation | 4.17 Million USD | -3.183% |
| Bioxytran, Inc. | 1.92 Million USD | -123.948% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6807.215% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -97.671% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 48.16% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 49.785% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -177.149% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1508.582% |
| Neutra Corp. | 54.15 Thousand USD | -7860.337% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -135.574% |
| PureTech Health plc | 25.51 Million USD | 83.102% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -252.141% |
| IXICO plc | 472.02 Thousand USD | -813.303% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 72.189% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 93.076% |
| CSL Limited | 12.18 Billion USD | 99.965% |
| Cellectis S.A. | 92.77 Million USD | 95.353% |